全文获取类型
收费全文 | 52748篇 |
免费 | 7592篇 |
国内免费 | 1387篇 |
专业分类
耳鼻咽喉 | 245篇 |
儿科学 | 1061篇 |
妇产科学 | 590篇 |
基础医学 | 2853篇 |
口腔科学 | 2343篇 |
临床医学 | 8326篇 |
内科学 | 5532篇 |
皮肤病学 | 780篇 |
神经病学 | 2951篇 |
特种医学 | 792篇 |
外国民族医学 | 9篇 |
外科学 | 5057篇 |
综合类 | 9750篇 |
现状与发展 | 7篇 |
一般理论 | 26篇 |
预防医学 | 4789篇 |
眼科学 | 802篇 |
药学 | 6840篇 |
481篇 | |
中国医学 | 5505篇 |
肿瘤学 | 2988篇 |
出版年
2024年 | 90篇 |
2023年 | 1228篇 |
2022年 | 1525篇 |
2021年 | 3122篇 |
2020年 | 3675篇 |
2019年 | 2679篇 |
2018年 | 2482篇 |
2017年 | 2827篇 |
2016年 | 2765篇 |
2015年 | 2362篇 |
2014年 | 4027篇 |
2013年 | 4436篇 |
2012年 | 3539篇 |
2011年 | 3633篇 |
2010年 | 2822篇 |
2009年 | 2483篇 |
2008年 | 2411篇 |
2007年 | 2464篇 |
2006年 | 2143篇 |
2005年 | 1762篇 |
2004年 | 1499篇 |
2003年 | 1332篇 |
2002年 | 1077篇 |
2001年 | 854篇 |
2000年 | 678篇 |
1999年 | 496篇 |
1998年 | 403篇 |
1997年 | 374篇 |
1996年 | 321篇 |
1995年 | 273篇 |
1994年 | 273篇 |
1993年 | 195篇 |
1992年 | 213篇 |
1991年 | 178篇 |
1990年 | 147篇 |
1989年 | 154篇 |
1988年 | 134篇 |
1987年 | 120篇 |
1986年 | 81篇 |
1985年 | 95篇 |
1984年 | 75篇 |
1983年 | 40篇 |
1982年 | 48篇 |
1981年 | 39篇 |
1980年 | 39篇 |
1979年 | 24篇 |
1978年 | 12篇 |
1977年 | 15篇 |
1976年 | 17篇 |
1975年 | 19篇 |
排序方式: 共有10000条查询结果,搜索用时 140 毫秒
31.
Alexander D. Sherry MD Kelsey L. Corrigan MD MPH Ramez Kouzy MD Joseph Abi Jaoude MD Yumeng Yang MS Roshal R. Patel MD Douglas J. Totten MD MBA Neil B. Newman MD MS Prajnan Das MD MS MPH Cullen Taniguchi MD PhD Bruce Minsky MD Rebecca A. Snyder MD MPH C. David Fuller MD PhD Ethan Ludmir MD 《Cancer》2023,129(21):3430-3438
32.
Derek K. Chu Romina Brignardello-Petersen Gordon H. Guyatt Cristian Ricci Jon Genuneit 《Pediatric allergy and immunology》2022,33(1):e13609
Network meta-analyses (NMAs) simultaneously estimate the effects of multiple possible treatment options for a given clinical presentation. For allergists to benefit optimally from NMAs, they must understand the process and be able to interpret the results. Through a worked example published in Pediatric Allergy and Immunology, we summarize how to identify credible NMAs and interpret them with a focus on recent innovations in the GRADE approach (Grading of Recommendations Assessment, Development, and Evaluation). NMAs build on traditional systematic reviews and meta-analyses that consider only direct paired comparisons by including indirect evidence, thus allowing the simultaneous assessment of the relative effect of all pairs of competing alternatives. Our framework informs clinicians of how to identify credible NMAs and address the certainty of the evidence. Trustworthy NMAs fill a critical gap in providing key inferences using direct and indirect evidence to inform clinical decision making when faced with more than two competing courses of treatment options. This document will help allergists to identify trustworthy NMAs to enhance patient care. 相似文献
33.
34.
目的观察耳穴贴压联合俞募配穴针刺治疗中风后便秘(虚秘)的临床疗效。方法将80例中风后便秘(虚秘)患者随机分为治疗组40例、对照组40例。在中风常规治疗、护理及康复训练下,治疗组采用耳穴贴压联合俞募配穴针刺,对照组采用普通针刺法。对两组患者临床疗效、便秘症状积分、胃肠激素水平及生存质量进行比较。结果两组治疗后胃肠激素P物质(SP)水平及便秘患者生存质量量表(PAC-QOL)评分均有显著提高(P<0.01),且治疗组治疗后明显高于对照组(P<0.01),两组治疗后便秘症状积分、胃肠激素血管活性肠肽(VIP)水平均显著降低(P<0.01),且治疗组治疗后低于对照组(P<0.01)。治疗组总有效率为87.5%,两组疗效比较差异有统计学意义(P<0.05)。结论耳穴贴压联合俞募配穴针刺治疗中风后便秘(虚秘)具有良好疗效。 相似文献
35.
Darren Ming‐Chun Poon 《Asia-Pacific Journal of Clinical Oncology》2020,16(Z3):18-23
For advanced and metastatic urothelial carcinomas (UCs), platinum (preferably cisplatin)‐based chemotherapy has been the standard treatment for many years. However, many patients are ineligible for cisplatin‐based chemotherapy because of poor performance status and/or other age‐related conditions. At the other end of the spectrum, patients with localized non‐muscle–invasive bladder cancer who are unresponsive to intravesical Bacillus Calmette‐Guérin (BCG) treatment often face radical cystectomy as the only option. In recent years, the application of immunotherapy in the form of immune‐checkpoint inhibitors has provided viable alternatives in the second‐line postplatinum and first‐line cisplatin‐ineligible settings. Recent and ongoing clinical trials are also assessing the safety and efficacy of immunotherapy for neoadjuvant and adjuvant uses before/after cystectomy, for BCG‐unresponsive cases, and for combination treatments that include the newer indoleamine 2,3‐dioxygenase‐1 inhibitors and/or BCG. This review summarizes recent developments in immunotherapy for UCs. 相似文献
36.
目的研究多元化教学模式在骨科临床教学中的开展效果及价值。方法选取2018年1月-2019年7月在我院骨科实习的94名医学生,采用随机数字表法进行分组,为47名参照组学生采用传统教学方法,为47名学生采用多元化教学模式,对比二组学生的考核成绩与学生满意度。结果实验组学生的理论知识评分、实际操作评分、总成绩均高于参照组,实验组学生对教学方法的满意度(97.87%)也明显高于参照组(85.11%),经统计P<0.05,组间比较差异具有统计学分析价值。结论在骨科临床教学中,开展多元化教学模式,对提升教学效果与学生满意度均有积极帮助。 相似文献
37.
Takafumi Koyama Toshio Shimizu Satoru Iwasa Yutaka Fujiwara Shunsuke Kondo Shigehisa Kitano Kan Yonemori Akihiko Shimomura Sakura Iizumi Tatsuya Sasaki Junji Furuse Noboru Yamamoto 《Cancer science》2020,111(2):571-579
Fibroblast growth factor receptors (FGFR) are a family of transmembrane receptor tyrosine kinases involved in regulating cellular processes. FGFR mutations are implicated in oncogenesis, representing therapeutic potential in the form of FGFR inhibitors. This phase I, first‐in‐human study in Japan evaluated safety and tolerability of E7090, a potent selective FGFR1‐3 inhibitor, in patients with advanced solid tumors. Dose escalation (daily oral dose of 1‐180 mg) was carried out to assess dose‐limiting toxicity (DLT), maximum tolerated dose, and pharmacokinetics. Pharmacodynamic markers (serum phosphate, fibroblast growth factor 23, and 1,25‐(OH)2‐vitamin D) were also evaluated. A total of 24 patients refractory to standard therapy or for whom no appropriate treatment was available were enrolled. No DLT were observed up to the 140‐mg dose; one patient in the 180‐mg cohort experienced a DLT (increased aspartate aminotransferase/alanine aminotransferase, grade 3). The maximum tolerated dose was not reached. Dose‐dependent increases in the maximum concentration and area under the curve from time 0 to the last measurable concentration were observed up to 180 mg. Dose‐dependent increases were observed in all pharmacodynamic markers and plateaued at 100‐140 mg, indicating sufficient FGFR pathway inhibition at doses ≥100 mg. In conclusion, E7090 showed a manageable safety profile with no DLT at doses ≤140 mg. Maximum tolerated dose was not determined. The recommended dose for the follow‐up expansion part, restricted to patients with tumors harboring FGFR alterations, was determined as 140 mg, once daily. 相似文献
38.
ABSTRACT
Introduction
Acne is a chronic, inflammatory, and immune mediated disease of pilosebaceous unit, highly prevalent in adolescents. It involves face, trunk, and back; may leave scars and affect quality of life. Early, effective, and safe treatment is the key for disease resolution. Oral isotretinoin is the unique treatment for cure or prolonged remission for moderate and severe acne, preventing psychosocial impact and scars. It inhibits sebaceous glands activity and has anti-inflammatory and immunoregulatory properties. 相似文献39.
目的探究急诊护理临床带教中采用情景模拟、案例讨论联合教学法效果。方法在本院实习的若干名护生中,选取124名护生分按照教学方法分组,对照组62名实施传统急诊护理带教,观察组62名实施案例讨论、情景模拟联合教学法,对比临床带教效果。结果两组实践与理论成绩相比,观察组成绩更高(P<0.05)。思维、急救及应激能力自我评价相比,观察组的总提高率高于对照组(P<0.05)。实施案例分析结合情景模拟教学模式后,问卷调查中观察组无护生不赞同此模式,非常赞同此教学模式的护生占总人数的90%以上。结论实施案例讨论、情景模拟联合教学模式后,护生急诊护理实践与理论水平均提升,护生我评价较高。 相似文献
40.
赵阳 《中国继续医学教育》2020,(4):142-144
目的分析米非司酮和宫瘤消胶囊的联合应用对子宫肌瘤的临床治疗效果。方法本研究对象为80例子宫肌瘤患者,收治时间均在2017年3月—2018年3月期间。将上述子宫肌瘤患者随机分成两组,各40例。给予对照组患者口服米非司酮进行治疗,研究组患者在上述治疗的基础上增加宫瘤消胶囊口服治疗,记录2组患者治疗效果,性激素水平及子宫体积及肿瘤体积变化。结果(1)研究组患者的总体有效率显著高于对照组;(2)研究组患者的P、E2、LH及FSH均显著低于对照组;(3)研究组患者子宫体积及肿瘤体积均显著低于对照组。结论米非司酮片和宫瘤消胶囊的联合治疗对子宫肌瘤患者的治疗效果较显著。 相似文献